Clinical trial
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in…
NCT00273910 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00273910 |
|---|---|
| Title | Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma |
| Official title | Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | High-Risk Melanoma |
| Intervention type | Drug |
| Interventions | gp100:209-217 (210M), Montanide ISA-51, Imiquimod |
| Enrollment | 104 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jan 9, 2006 |
| Last update posted | Oct 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: